Glyxambi
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Glyxambi is a fixed-dose combination of sodium-glucose cotransporter-2 inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) and dipeptidyl peptidase-IV inhibitor Tradjenta (linagliptin; Boehringer Ingelheim/Eli Lilly). Both linagliptin and empagliflozin were originally developed by Boehringer Ingelheim. Under the terms of the partnership between Boehringer Ingelheim and Eli Lilly, Glyxambi revenues across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) will be shared equally between the two companies.
Glyxambi first launched in the US in 2015. Two dosages are available: a 25mg empagliflozin + 5mg linagliptin tablet, and a 10mg empagliflozin + 5mg linagliptin tablet.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Glyxambi : Diabetes type 2
LIST OF FIGURES
7 Figure 1: Glyxambi for type 2 diabetes – SWOT analysis
8 Figure 2: Datamonitor Healthcare drug assessment scorecard for Glyxambi compared to Januvia
9 Figure 3: Datamonitor Healthcare drug assessment scorecard for Glyxambi compared to Januvia
LIST OF TABLES
5 Table 1: Glyxambi drug profile
6 Table 2: Overview of pivotal trial data for Glyxambi in diabetes
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sotagliflozin 
Sign up to the